Elderly patients with CML - Chronic Myeloid Leukemia
Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia.
August 29, 2019, PubMed
What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?
April 5, 2019, Expert Opinion
Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia
December, 2017, ASH 2017
Female and Elderly Chronic Myeloid Leukemia Patients Often Do Not Receive an Adequate TKI Treatment
Blood 2016, Journal Blood
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
September 18, 2015, PublMed
Study Reveals No Impact of Age on Outcome in Chronic Myeloid Leukemia Patients Treated With Imatinib
March 30,2011, PRNewsWire
Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
February 2011, PublMed
Treatment of the elderly population with haematological cancers: What's new from the American Society of Hematology 2010 meeting?
December 8, 2010, ecancernews
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance
December 6, 2010, ASH 2010
Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML
December 5,2010,ASH 2010
Imatinib In Very Elderly CML Patients: What Can We Achieve?
December 4, 2010 , ASH 2010
Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
December 2008, ASH 2008
Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment
September 2005, Leukemia Research
An 85-Year-Old Japanese Woman with Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia with Del (5q) Successfully Treated by Intermittent Imatinib Therapy
September 23, 2004. Journal of the American Geriatrics Society
August 29, 2019, PubMed
What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?
April 5, 2019, Expert Opinion
Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia
December, 2017, ASH 2017
Female and Elderly Chronic Myeloid Leukemia Patients Often Do Not Receive an Adequate TKI Treatment
Blood 2016, Journal Blood
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
September 18, 2015, PublMed
Study Reveals No Impact of Age on Outcome in Chronic Myeloid Leukemia Patients Treated With Imatinib
March 30,2011, PRNewsWire
Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
February 2011, PublMed
Treatment of the elderly population with haematological cancers: What's new from the American Society of Hematology 2010 meeting?
December 8, 2010, ecancernews
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance
December 6, 2010, ASH 2010
Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML
December 5,2010,ASH 2010
Imatinib In Very Elderly CML Patients: What Can We Achieve?
December 4, 2010 , ASH 2010
Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
December 2008, ASH 2008
Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment
September 2005, Leukemia Research
An 85-Year-Old Japanese Woman with Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia with Del (5q) Successfully Treated by Intermittent Imatinib Therapy
September 23, 2004. Journal of the American Geriatrics Society
